Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors

Abstract

Introduction2-Deoxy-2-[18F]fluoro-D-glucose PET/CT is a well-established imaging method for staging, restaging and therapy-control in human medicine. In veterinary medicine, this imaging method could prove to be an attractive and innovative alternative to conventional imaging in order to improve staging and restaging. The aim of this study was both to evaluate the effectiveness of this image-guided method in canine patients with spontaneously occurring cancer as well as to illustrate the dog as a well-suited animal model for comparative oncology.MethodsTen dogs with various malignant tumors were included in the study and underwent a whole body FDG PET/CT. One patient has a second PET-CT 5 months after the first study. Patients were diagnosed with histiocytic sarcoma (n = 1), malignant lymphoma (n = 2), mammary carcinoma (n = 4), sertoli cell tumor (n = 1), gastrointestinal stromal tumor (GIST) (n = 1) and lung tumor (n = 1). PET/CT data were analyzed with the help of a 5-point scale in consideration of the patients’ medical histories.ResultsIn seven of the ten dogs, the treatment protocol and prognosis were significantly changed due to the results of FDG PET/CT. In the patients with lymphoma (n = 2) tumor extent could be defined on PET/CT because of increased FDG uptake in multiple lymph nodes. This led to the recommendation for a therapeutic polychemotherapy as a treatment. In one of the dogs with mammary carcinoma (n = 4) and in the patient with the lung tumor (n = 1), surgery was cancelled due to the discovery of multiple metastasis. Consequently no treatment was recommended.ConclusionFDG PET/CT offers additional information in canine patients with malignant disease with a potential improvement of staging and restaging. The encouraging data of this clinical study highlights the possibility to further improve innovative diagnostic and staging methods with regard to comparative oncology. In the future, performing PET/CT not only for staging but also in therapy control could offer a significant improvement in the management of dogs with malignant tumors.

Prevalence, distribution, and clinical characteristics of hemangiosarcoma‐associated skeletal muscle metastases in 61 dogs: A whole body computed tomographic study

“…In a recent study in humans, the detection rate of SMMs by PET was 100% (51/51), whereas that of CT was 23.5% (12/51) . 18 F‐fluoro‐2‐deoxyglucose ( 18 F‐FDG)‐PET‐CT provides information otherwise not obtainable using conventional diagnostic tools, potentially improving the quality of staging and management of dogs with cancer . 18 F‐fluoro‐2‐deoxyglucose is the most commonly used PET radiopharmaceutical in oncology because this isotope maps glucose metabolism in the body, and because tumor cells often use more glucose than normal cells, 18 F‐FDG is an excellent tool to detect neoplastic tissue .…”

18F‐sodium fluoride positron emission tomography of the equine distal limb: Exploratory study in three horses

“…This technique complements the structural/morphological imaging capability of modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) . Positron emission tomography is well established as an invaluable clinical diagnostic imaging modality, particularly in oncological and neurological studies using the radiotracer 18 F‐fluorodeoxyglucose ( 18 F‐FDG) . A wide variety of other PET radiotracers are also available for imaging various metabolic, molecular, or physiological targets of interest.…”

Prognostic value of fluorine18flourodeoxyglucose positron emission tomography/computed tomography in dogs with appendicular osteosarcoma

“…Fluorine 18 flourodeoxyglucose positron emission tomography/computed tomography is a relatively new staging method in veterinary medicine. There are multiple case series evaluating this modality but only a few studies have examined the effectiveness of 18 F‐FDG PET/CT as a staging method to evaluate for metastasis or concurrent neoplasia . Larger scale investigation into the utility of 18 F‐FDG PET/CT staging has not been previously reported in veterinary medicine.…”